LLY vs WVE
LLY: A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth. WVE: A clinical-stage biotechnology company developing a versatile, multimodal RNA medicine platform to treat rare and common diseases without the need for complex delivery vehicles like lipid nanoparticles.
Side-by-side fundamentals
| Metric | LLY | WVE | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $1,197.53 | $5.92 | |
| Market cap as of 2026-07-30 | $1.15T | $1.1B | |
| P/E as of 2026-07-30 | 45.62 | n/a | |
| PEG as of 2026-07-30 | 1.37 | -0.11 | WVE lower |
| Net margin as of 2026-07-30 | +35.0% | -255.7% | LLY higher |
| Gross margin as of 2026-07-30 | +82.8% | n/a | |
| Operating margin as of 2026-07-30 | +43.6% | -274.2% | LLY higher |
| ROE as of 2026-07-30 | +101.3% | -55.7% | LLY higher |
| ROA as of 2026-07-30 | +22.7% | -42.8% | LLY higher |
| Debt / equity as of 2026-07-30 | 1.39 | 0.00 | WVE lower |
| Revenue growth (YoY) as of 2026-07-30 | +47.4% | -31.6% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | +127.1% | WVE higher |
| Dividend yield as of 2026-07-30 | +0.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-30 | 0.50 | -1.33 | |
| 1-year return as of 2026-07-27 close | +47.4% | -29.5% | LLY higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.